Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth.
We have recently demonstrated that a DNA vaccine targeting membrane-bound KIT ligand (KITL) inhibits tumor growth by interfering with vessel stabilization/permeability and by disrupting the recruitment of inflammatory cells and regulatory T cells, the latter being an essential mechanism by which tumors resist available treatments. Combining KITL-targeting vaccines with conventional chemotherapy might avert drug resistance and improve the efficacy of standard-of-care therapeutic interventions.
Department of Medical Sciences; University of Torino; Torino, Italy.
Patrizia
P
Dentelli
Molecular Biotechnology Center; University of Torino; Torino, Italy.
Federica
F
Cavallo
Department of Medical Sciences; University of Torino; Torino, Italy.
Maria Felice
MF
Brizzi
DNA vaccination; membrane-bound KITL; non-functional angiogenesis